Medical Marijuana Analyst Coverage Initiated: Brief Report By Brokerbank Securities, Inc. — New York, Oct. 22, 2014 /prnewswire/ —

PR Newswire

A large portion of the medical research going on is focused on the cannabinoids in Marijuana. There are 80+ of these cannabinoids in the cannabis plant and researchers think many of them may help medically with different things. MJNA services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. It also offers pre-and-post production tracking, gemplasm references, and packaging and processing services. These products are often expensive companies making tinctures, capsules or creams infused with CBD-rich hemp must import the plant from outside the U.S. It’s a process that is, not surprisingly, strictly regulated (translation: costly). But the market for these types of legal alternatives to marijuana may be growing. HempMeds which makes CBD infused products says they sell about $1 million in products each month. HempMeds’ parent company, Medical Marijuana Inc. ( MJNA ), says that through all of its divisions, it’s sold some $60 million worth of CBD-only, THC-free products so far this year. Medical Marijuana, Inc. is based in San Diego, California.
To read more visit http://www.prnewswire.com/news-releases/medical-marijuana-analyst-coverage-initiated-brief-report-by-brokerbank-securities-inc-429019938.html

Comments are closed.